Stocks
Mutual Funds
ETFs
Pro Tools
Terminal
WealthView
Pricing
Learn More
stocksPPLPHARMA
resources
PPLPHARMA
190.85-4.1 (-2.12%)
23 Oct, 12:00 AM

Annual Reports and Financial Documents

Piramal Pharma Ltd. annual reports, quarterly results, earnings call transcripts and investor presentations. All official filings in one place.

Corporate Announcements and Regulatory Filings

Piramal Pharma Ltd. BSE/NSE disclosures, board meeting outcomes, insider trading notifications, acquisitions and other regulatory filings.
  1. Analyst / Investor Meet16 Oct 2026
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
    Please find enclosed intimation of Conference Call with Investors/Analysts under the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 ('SEBI Listing Regulations')
  2. Board Meeting16 Oct 2026
    Board Meeting Intimation for Considering And Approving The Unaudited Financial Results (Standalone And Consolidated) Of The Company For Quarter And Half Year Ended 30Th September, 2026
    Piramal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 ,inter alia, to consider and approve the Unaudited Financial Results ....
  3. General1 Oct 2026
    Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Expiry And Non-Renewal Of Commercial Arrangement With Bayer Pharmaceuticals Private Limited
    Please refer attachment.
  4. General1 Oct 2026
    Clarification On News Item Which Appeared In The
    Please refer attachment.
  5. Change in Management30 Sept 2026
    Announcement under Regulation 30 (LODR)-Change in Management
    Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 -Appointment of Senior Management Personnel.
  6. Change in Management30 Sept 2026
    Announcement under Regulation 30 (LODR)-Change in Management
    Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Changes in Senior Management Personnel.
  7. Closure of Trading Window29 Sept 2026
    Closure of Trading Window
    Please refer the attachment.
  8. General29 Sept 2026
    Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
    Please refer attachment.
  9. General18 Sept 2026
    Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 - ESG Rating -Niche Ninety
    Please refer attached file
  10. General14 Sept 2026
    Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 - FDA Inspection
    Please refer attached file
  11. Analyst / Investor Meet8 Sept 2026
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
    Please refer attached file
  12. General3 Sept 2026
    Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 - ESG Rating
    Please refer attached file
  13. Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 201126 Aug 2026
    Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
    The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Deutsche Bank AG
  14. General24 Aug 2026
    Sustainability Report Of Piramal Pharma Limited For The Financial Year 2025-26
    Please refer attached file
  15. Acquisition18 Aug 2026
    Announcement under Regulation 30 (LODR)-Acquisition
    Please find enclosed intimation of acquisition of additional stake in Yapan Bio Private Limited
  16. Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 201118 Aug 2026
    Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
    The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Deutsche Bank AG
  17. General10 Aug 2026
    Announcement Under Regulation 30 (LODR)- Exercise Of Call Option For Acquisition Of Additional Equity Stake In Yapan Bio Private Limited
    Please find enclosed intimation of exercise of call option for acquisition of additional equity stake in Yapan Bio Private Limited
  18. Analyst / Investor Meet10 Aug 2026
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
    Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
  19. General3 Aug 2026
    Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 -Resumption Of Operations At Company'S Facilities Located At Ahmedabad, Gujarat
    Please refer attachment
  20. AGM30 Jul 2026
    Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
    Report of the Scrutinizer along with the voting results of the businesses transacted at the AGM

Frequently Asked Questions

Where can I download the annual report of Piramal Pharma Ltd.?
Annual reports of Piramal Pharma Ltd. are available for download in the Annual Reports and Financial Documents section of the Resources tab, organised by financial year.
Where can I find the quarterly results of Piramal Pharma Ltd.?
Quarterly earnings results and presentations of Piramal Pharma Ltd. are available in the Annual Reports and Financial Documents section of the Resources tab. Detailed financials are also in the Statements tab.
Does Piramal Pharma Ltd. publish earnings call transcripts?
Earnings call transcripts of Piramal Pharma Ltd., where available, are listed in the Annual Reports and Financial Documents section of the Resources tab.
Where can I find investor presentations of Piramal Pharma Ltd.?
Investor presentations and annual day presentations of Piramal Pharma Ltd. are listed in the Resources tab under Annual Reports and Financial Documents.
What are the recent corporate announcements of Piramal Pharma Ltd.?
Corporate announcements and regulatory filings of Piramal Pharma Ltd. as submitted to BSE and NSE are available in the Corporate Announcements and Regulatory Filings section of the Resources tab.
How do I access the regulatory filings of Piramal Pharma Ltd.?
Regulatory filings including board meeting outcomes, insider trading disclosures and other exchange notifications of Piramal Pharma Ltd. are in the Corporate Announcements and Regulatory Filings section of the Resources tab.
What is the ISIN of Piramal Pharma Ltd.?
The ISIN (International Securities Identification Number) of Piramal Pharma Ltd. is INE0DK501011. This is the unique identifier used across exchanges and depositories.
On which stock exchange is Piramal Pharma Ltd. listed?
Piramal Pharma Ltd. is listed on NSE and BSE. The NSE symbol is PPLPHARMA and the BSE code is -.
Where can I find the shareholding pattern of Piramal Pharma Ltd.?
The quarterly shareholding pattern of Piramal Pharma Ltd. showing promoter, FII, DII, mutual fund and public holdings is available in the Shareholding Pattern section on the Overview tab.
How current is the data for Piramal Pharma Ltd. on Sharpely?
Share price data for Piramal Pharma Ltd. is updated as of 23 Oct 2026. Financial statements, shareholding and other fundamental data are updated after each quarterly disclosure.